Symbiotec Pharmalab Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Symbiotec Pharmalab Ltd filed with BSE on 28 Sept 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Symbiotec Pharmalab reported consolidated revenue of Rs 218 crore for Q1 FY27, up 7% year-on-year, driven largely by its API business which grew 6% with gross margins above 60%. Consolidated EBITDA stood at Rs 45 crore and net profit at about Rs 14 crore, which management said were impacted by operating expenses and depreciation from the new biotech CDMO and complex injectables businesses that have not yet generated revenue. Management reiterated guidance of 20-25% growth in revenue and EBITDA for the fiscal year, with new business revenues expected to begin in the next 6 to 12 months.
Numbers mentioned
Consolidated revenue: INR218 crores (Q1 FY27)
p. 9
“Consolidated revenue for quarter one FY ‘27 stood at INR218 crores, representing a growth of 7% year-on-year.”
Raghavender R., page 9 of the filed PDF · View the filing
API business revenue growth: 6% year-on-year (Q1 FY27)
p. 9
“This revenue was largely contributed by our API business, with revenues at INR215 crores and a growth of 6% year-on-year driven largely by volume increase.”
Raghavender R., page 9 of the filed PDF · View the filing
API gross margin: 60% plus (Q1 FY27)
p. 9
“Gross margins in the API business remains strong at 60% plus for quarter one FY ‘27, and API EBITDA for quarter one FY ‘27 stood at INR66 crores, a steady 9% year-on-year growth driven by sales volume growth and a strong gross margin mix.”
Raghavender R., page 9 of the filed PDF · View the filing
Consolidated EBITDA: INR45 crores (Q1 FY27)
p. 9
“The consolidated EBITDA for quarter one is INR45 crores, and net profit is about INR14 crores.”
Raghavender R., page 9 of the filed PDF · View the filing
New business operating expense drag: INR23 crores (Q1 FY27)
p. 9
“this may not be a true reflection of our underlying profitability due to the expenses drag from new businesses, which is about INR23 crores of operating expenses and INR11 crores of depreciation.”
Raghavender R., page 9 of the filed PDF · View the filing
Net debt: INR398 crores (as on 30th June 2026)
p. 9
“our net debt position as on 30th June stood at INR398 crores, and with the recent IPO proceeds of INR142 crores, which is net of expenses, and considering further capex in the September quarter, our net debt as of today roughly stands around INR326 crores.”
Raghavender R., page 9 of the filed PDF · View the filing
Capex: approximately INR68 crores (Q1 FY27)
p. 9
“Our capex for quarter one FY ‘27 is approximately INR68 crores.”
Raghavender R., page 9 of the filed PDF · View the filing
Cumulative API facility investment: more than INR650 crores
p. 7
“in our existing API facility, which is Rau site and the Pithampur SEZ site, we have cumulatively invested more than INR650 crores over the years, helping us generate around INR900 crores of API revenue at an asset turnover ratio of about 1.5x.”
Anil Satwani, page 7 of the filed PDF · View the filing
New facilities investment: close to INR1,000 crores
p. 7
“we have also invested close to INR1,000 crores in two new facilities, which I just talked about.”
Anil Satwani, page 7 of the filed PDF · View the filing
API business gross block: close to INR640 crores (as of 30th June)
p. 15
“we have roughly invested close to INR640 crores, which is the gross block as of 30th June.”
Raghavender R., page 15 of the filed PDF · View the filing
API capacity utilization: 70%-80%
p. 15
“It's roughly about 70%-80%, Sagar.”
Raghavender R., page 15 of the filed PDF · View the filing
Milestone revenue recognized last year: INR33 crores (Q4 FY26)
p. 17
“last year, we recognized roughly about INR33 crores, which was in fourth quarter, and you would see that in the numbers.”
Raghavender R., page 17 of the filed PDF · View the filing
R&D spend as percentage of sales: 3% to 5%
p. 7
“consistently invested 3% to 5% of our sales in R&D over the years, which is reflecting a sustained commitment to our innovation.”
Anil Satwani, page 7 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — 20% · FY27
stated conditionally by Anil Satwani
p. 8
“we are definitely targeting 20% and 25% growth for this current fiscal year in our revenues and our EBITDA, respectively. Of course, this could be plus-minus some percentage, 5%, due to this global operating environmental uncertainties that we are all aware of today.”
Anil Satwani, page 8 of the filed PDF · View the filing
EBITDA growth — 25% · FY27
stated conditionally by Anil Satwani
p. 8
“we are definitely targeting 20% and 25% growth for this current fiscal year in our revenues and our EBITDA, respectively. Of course, this could be plus-minus some percentage, 5%, due to this global operating environmental uncertainties that we are all aware of today.”
Anil Satwani, page 8 of the filed PDF · View the filing
New business revenue commencement — next 6 to 12 months
stated firmly by Anil Satwani
p. 7
“we should start seeing first of these revenues new revenues in the next 6 to 12 months.”
Anil Satwani, page 7 of the filed PDF · View the filing
New business operating expense run rate — INR23 crores · next two to three quarters
stated conditionally by Raghavender R.
p. 14
“this INR23 crores as a run rate should more or less continue for the next two, three quarters in terms of the run rate of expenses, and similarly on the depreciation about INR11 crores.”
Raghavender R., page 14 of the filed PDF · View the filing
Capex for new growth drivers — INR200 crores to INR250 crores each year · next two to three years
stated conditionally by Anil Satwani
p. 14
“the visibility that I can currently give you based on our operating cash flows is minimum INR200 crores to INR250 crores each year for the next two to three years.”
Anil Satwani, page 14 of the filed PDF · View the filing
Fermentation capacity expansion (Phase 1) — 600 KL · 15 to 18 months
stated firmly by Anil Satwani
p. 13
“this 600 KL is with a customer whom we have already signed the term sheet with, and we should be going ahead with this construction starting Q3 itself as '27.”
Anil Satwani, page 13 of the filed PDF · View the filing
API gross margin — around 60%
stated as an aspiration by Anil Satwani
p. 12
“we'll continue to do gross margins around 60%. Of course, we are currently much higher than 60%, but I think that's the base that that we expect our business to continue with.”
Anil Satwani, page 12 of the filed PDF · View the filing
API EBITDA margin — close to 30%
stated as an aspiration by Anil Satwani
p. 12
“similarly on the EBITDA lines, we are we are very close to 30% margins, and this is what we'd like to maintain.”
Anil Satwani, page 12 of the filed PDF · View the filing
DCV term sheet signing — early Q3 FY27
stated conditionally by Anil Satwani
p. 7
“this definitive agreement is at the very advanced stage, and we expect it to be signed in early Q3 FY27.”
Anil Satwani, page 7 of the filed PDF · View the filing
R&D as percentage of sales — about 5% · future
stated as an aspiration by Raghavender R.
p. 17
“we consistently have been investing about 3% to 4% of our sales as R&D, and we expect this to continue, probably with a slight increase as well to about 5% in the future.”
Raghavender R., page 17 of the filed PDF · View the filing
Biologics/insulin revenue commencement — early next fiscal year
stated conditionally by Anil Satwani
p. 15
“the revenues from our biologics division is likely to kick in, in early next fiscal year.”
Anil Satwani, page 15 of the filed PDF · View the filing
New businesses gross and EBITDA margins at maturity — higher than 70% gross margins and higher than 35% EBITDA margins
stated as an aspiration by Anil Satwani
p. 18
“this industry trend is higher than 70% as gross margins and higher than 35% as EBITDA margins.”
Anil Satwani, page 18 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said existing capacity is largely booked and they expect to build four times the current capacity over the next 2-3 years, with each contract representing a multi-million dollar opportunity, though specific numbers could not be disclosed due to confidentiality.
Answered by Anil Satwani
Asked by Saion Mukherjee: How should investors think about fermentation capacity ramp-up and revenue potential over a 5-year horizon, and how do the take-or-pay contracts work?
p. 11
“All I can tell you at the high level, each of this contract is multi-million dollars of an opportunity coming from phase 0 itself, which is essentially our own existing 400 kL facility.”
Anil Satwani, page 11 of the filed PDF · View the filing
Management said the API business margins are fairly predictable due to backward integration and shifting product/geography mix toward regulated markets and long-term customers.
Answered by Anil Satwani
Asked by Saion Mukherjee: How sustainable are the API business growth and margin numbers going into FY28?
p. 12
“I don't see any reason why would this profile change. I think we have been actually consolidating our profit margins, as you have seen, because we are moving more and more towards the regulated markets”
Anil Satwani, page 12 of the filed PDF · View the filing
Management said five to six products have already been developed and are moving toward validation, with capacity rather than product count being the current constraint.
Answered by Anil Satwani
Asked by Tushar Manudhane: How many more DCV products will be filed over the next 12-24 months?
p. 13
“there are five to six products that have been developed. They're getting into the validation at the plant level very, very soon.”
Anil Satwani, page 13 of the filed PDF · View the filing
The CFO said the expense and depreciation run rate should continue for the next two to three quarters with only small inflationary increases.
Answered by Raghavender R.
Asked by Harith Ahamed: How should the INR23 crore new business opex run rate be modeled for the rest of FY27?
p. 14
“this INR23 crores as a run rate should more or less continue for the next two, three quarters in terms of the run rate of expenses, and similarly on the depreciation about INR11 crores.”
Raghavender R., page 14 of the filed PDF · View the filing
Management said confidentiality prevents exact figures but the opex drag will be offset by milestone revenues in Q3 and Q4, and biologics revenue is expected only in early next fiscal year.
Answered by Anil Satwani
Asked by Harith Ahamed: What will trigger the expected milestone revenues in H2, and will there be any other new business revenues in FY27?
p. 15
“all this opex will be set off by this lumpy revenue that we will have in Q3, Q4 as part of our milestone.”
Anil Satwani, page 15 of the filed PDF · View the filing
The CFO said roughly INR640 crore gross block has been invested in the API business, generating INR800-900 crore of revenue, with utilization at 70-80%.
Answered by Raghavender R.
Asked by Sagar Tanna: How much capex has been incurred for the API business and what is current capacity utilization?
p. 15
“we have roughly invested close to INR640 crores, which is the gross block as of 30th June.”
Raghavender R., page 15 of the filed PDF · View the filing
Management confirmed guidance is on a consolidated basis and said PAT growth will be lower than EBITDA growth due to depreciation drag, but cash PAT growth should be upwards of 25%.
Answered by Raghavender R.
Asked by Anubhav Sahu: Is the 20-25% guidance at the consolidated level, and what is the net profit trajectory expected?
p. 16
“if you look at cash PAT, which is PAT plus depreciation, then the growth is upwards of 25% as mentioned by Anil for EBITDA.”
Raghavender R., page 16 of the filed PDF · View the filing
Management said the capex will be funded by internal accruals plus partner capital, and clarified the arrangement is a time-based take-or-pay CMO service with no profit sharing.
Answered by Anil Satwani
Asked by Anubhav Sahu: What is the capex outlay for the 600 KL Phase 1 expansion and is it revenue-sharing with the customer?
p. 16
“this is more as a CMO service. We are not going to share any profit. It is on a -- it's a time-based.”
Anil Satwani, page 16 of the filed PDF · View the filing
The CFO said milestone revenues of about INR33 crore were recognized in Q4 FY26 but none were recognized in Q1 FY27 as such revenues are periodical rather than quarterly.
Answered by Raghavender R.
Asked by Kartick Bane: Were there revenues from complex injectables and CDMO last year, and why none this quarter?
p. 17
“this year in quarter one, we have not had any revenues from the CDMO and injectable.”
Raghavender R., page 17 of the filed PDF · View the filing
Management said it cannot give a timeline since the formulation development and FDA approval are controlled by its partner, not Symbiotec.
Answered by Anil Satwani
Asked by Raaj: When is the generic version of Premarin expected to launch in the API division?
p. 17
“at this point of time, I cannot give any guidance with respect to time for our Premarin generic launch as a formulation.”
Anil Satwani, page 17 of the filed PDF · View the filing
Management said API is currently more than 90% of sales but expects this to fall below half over a 5-6 year horizon as DCV and CDMO revenues grow.
Answered by Anil Satwani
Asked by Raaj: What will the sales composition look like in two years, with how much from the API segment?
p. 18
“this should be definitely less than half.”
Anil Satwani, page 18 of the filed PDF · View the filing
Management declined specific forward guidance but pointed to industry benchmarks of over 70% gross margin and over 35% EBITDA margin as the expected range.
Answered by Anil Satwani
Asked by Rohan Kampani: What gross and EBITDA margins should be expected for the CDMO and injectables businesses at mature utilization?
p. 18
“this industry trend is higher than 70% as gross margins and higher than 35% as EBITDA margins.”
Anil Satwani, page 18 of the filed PDF · View the filing
Risks flagged
Global operating environment uncertainties could cause guidance to vary by plus or minus a few percentage points
p. 8
“Of course, this could be plus-minus some percentage, 5%, due to this global operating environmental uncertainties that we are all aware of today.”
Anil Satwani, page 8 of the filed PDF · View the filing
Input costs such as logistics, shipping and solvent prices are not backward-integrated and can move margins
p. 12
“We don't know what goes through some logistics shipping costs changing, some solvent prices going up and down, where we are not backward-integrated.”
Anil Satwani, page 12 of the filed PDF · View the filing
Capacity constraints may limit ability to capture DCV demand despite having products ready
p. 13
“it looks like that we may have to come up with our second line very, very soon, because this capacity that we have is very limited already, and the traction is huge.”
Anil Satwani, page 13 of the filed PDF · View the filing
New business expenses and depreciation are recognized before corresponding revenues begin, distorting reported profitability
p. 9
“this may not be a true reflection of our underlying profitability due to the expenses drag from new businesses, which is about INR23 crores of operating expenses and INR11 crores of depreciation.”
Raghavender R., page 9 of the filed PDF · View the filing
Premarin generic API launch timeline depends on partner's formulation development and FDA approval, outside company's control
p. 17
“we are we are in no control over the formulation development.”
Anil Satwani, page 17 of the filed PDF · View the filing
Biologics revenue requires stability studies and DCGI approval before commercial sales can begin
p. 15
“we also need certain stability studies and get the approval from DCGI, even if it means we don't have to go for the clinical trials”
Anil Satwani, page 15 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.
Continue reading
- Symbiotec Pharmalab Ltd: filed results and exchange announcements
- Q1 FY27 results for every company Parakho holds
More Q1 FY27 earnings calls, in alphabetical order